Hypercalcemia in a Patient with Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia.
PMID: 31914196 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - December 16, 2019 Category: Cancer & Oncology Authors: Copur MS, Wedel W, Jonglertham P, Aprn CS, Horn A Tags: Oncology (Williston Park) Source Type: research

Breast Reconstruction in the Setting of Postmastectomy Radiotherapy: Controversies and Disparities.
Abstract The complex decision of breast reconstruction in the setting of postmastectomy radiotherapy (PMRT) involves an understanding of the indications of PMRT and weighing the risks and benefits of various reconstruction options suitable for each patient. Classic indications for PMRT include patients with at least T3 tumors, 4 or more positive lymph nodes, and/or positive surgical margins. The benefit of PMRT in patients with T1-T2 tumors with 1 to 3 positive lymph nodes, however, remains unclear. Breast reconstruction is known to improve quality of life in breast cancer patients. Reconstruction rates have conti...
Source: Oncology (Williston Park, N.Y.) - December 13, 2019 Category: Cancer & Oncology Authors: Ho TB, Wood WC, Mspt PDS Tags: Oncology (Williston Park) Source Type: research

Molecular Characterization and Treatment of Pancreatic Neuroendocrine Tumors.
PMID: 31914198 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - December 12, 2019 Category: Cancer & Oncology Authors: De Jesus-Acosta AMC Tags: Oncology (Williston Park) Source Type: research

Reassessing Cancer Survivorship in the Era of Personalized Medicine.
Authors: PMID: 31914199 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - December 12, 2019 Category: Cancer & Oncology Tags: Oncology (Williston Park) Source Type: research

The Future of CAR T-Cell Therapy.
PMID: 31914200 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - December 12, 2019 Category: Cancer & Oncology Authors: Slater H Tags: Oncology (Williston Park) Source Type: research

Novel Combination Shows Strong Antitumor Activity in Metastatic Renal Cell Carcinoma.
PMID: 31914201 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - December 12, 2019 Category: Cancer & Oncology Authors: Kahl KL Tags: Oncology (Williston Park) Source Type: research

Evaluating the Role of Targeted Therapy in Lung Cancer.
PMID: 31914202 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - December 12, 2019 Category: Cancer & Oncology Authors: Wakelee H Tags: Oncology (Williston Park) Source Type: research

Understanding Lung Cancer Treatment Advances.
Authors: PMID: 31914203 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - December 12, 2019 Category: Cancer & Oncology Tags: Oncology (Williston Park) Source Type: research

CLL14 Trial: Fixed-Duration Chemotherapy-Free Regimen for Frail Patients with Treatment-Na ïve CLL.
CLL14 Trial: Fixed-Duration Chemotherapy-Free Regimen for Frail Patients with Treatment-Naïve CLL. Oncology (Williston Park). 2019 Nov 14;33(11): Authors: Fakhri B, Andreadis C PMID: 31769861 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - November 14, 2019 Category: Cancer & Oncology Authors: Fakhri B, Andreadis C Tags: Oncology (Williston Park) Source Type: research

The Role of the Comprehensive Geriatric Assessment in the Evaluation of the Older Cancer Patient.
Abstract Geriatric assessments have now been recommended as part of the standard evaluation of an older adult considering cancer therapy. While the need for a more in-depth performance status evaluation of an older person with cancer was identified over 20 years ago, completion of a comprehensive geriatric assessment (CGA) is time-consuming and not frequently performed as part of the standard assessment of older cancer patients. Evidence suggests that incorporating such an evaluation could be useful for potentially determining the patient's chemotherapy tolerability or treatment completion, toxicity, and survival,...
Source: Oncology (Williston Park, N.Y.) - November 14, 2019 Category: Cancer & Oncology Authors: Blanquicett C, Cohen JB, Flowers C, Johnson T Tags: Oncology (Williston Park) Source Type: research

A Novel Combination Immunotherapy Approach for Neuroendocrine Tumors.
PMID: 31769863 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - November 14, 2019 Category: Cancer & Oncology Authors: Patel S Tags: Oncology (Williston Park) Source Type: research

Burnout in Oncology.
Abstract Burnout is defined as an occupational-related syndrome characterized by physical and emotional exhaustion, cynicism/depersonalization, and low sense of professional accomplishment. Multiple oncology-specific risk factors are associated with an increased susceptibility for the development of burnout. On a daily basis, oncologists are faced with life and death decisions and grieving much more frequently than are physicians in other specialties. Continuous exposure to fatal illnesses with limited success in curing them, exceedingly long work hours with more administrative time demands, limited autonomy over ...
Source: Oncology (Williston Park, N.Y.) - November 14, 2019 Category: Cancer & Oncology Authors: Copur MS Tags: Oncology (Williston Park) Source Type: research

What Are the Most Common Esophageal Metastases.
ez BM PMID: 31769865 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - November 14, 2019 Category: Cancer & Oncology Authors: Editor EDCS, Bourlon MT, Bolaños LM, Castro-Alonso FJ, Benitez BM Tags: Oncology (Williston Park) Source Type: research

2019 World Conference Of Lung Cancer Round-Up.
PMID: 31769866 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - November 14, 2019 Category: Cancer & Oncology Authors: Leavitt J, Pangilinan J Tags: Oncology (Williston Park) Source Type: research

Esmo Congress 2019: Focus on Breast Cancer.
PMID: 31769867 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - November 14, 2019 Category: Cancer & Oncology Authors: Saleh N, Copur MS Tags: Oncology (Williston Park) Source Type: research

Next Generation of Lung Cancer Management.
Abstract The most important lung cancer research falls under the hub of personalized medicine. There is an expanding list of lung cancer genotypes that researchers have identified as relevant, and even more importantly, that they have discovered targeted therapies for. In addition, scientists are learning more about predictive markers for immunotherapy that may inform clinicians on how to optimally treat patients. Both targeted therapy and immunotherapy are approved in advanced non-small cell lung cancer and oncologists are learning more about the utility for these drugs in earlier stage disease. PMID: 316611...
Source: Oncology (Williston Park, N.Y.) - October 28, 2019 Category: Cancer & Oncology Authors: Levy B Tags: Oncology (Williston Park) Source Type: research

Metastasis-Directed Therapy in Prostate Cancer. Why, When, and How?
Abstract Metastatic prostate cancer remains a life-limiting disease; while we have seen significant advances in systemic approaches which form the backbone of management, no curative paradigm yet exists. Metastasis-directed therapy (MDT) with stereotactic ablative radiotherapy (SABR) has emerged as a promising complementary technique for the management of low-volume metastatic prostate cancer. Herein we will review the rationale, potential benefits, and practical considerations associated with this approach. PMID: 31661149 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - October 28, 2019 Category: Cancer & Oncology Authors: Phillips RM, Deek MP, Deweese TL, Tran PT Tags: Oncology (Williston Park) Source Type: research

Immunotherapy Advances: 2019.
Abstract The year 2019 has offered up many advances in immunotherapy. These advances shed light on such important aspects as biomarkers, better targeted therapies, chemotherapy outcomes, and resistance. Summarized herein are several high-profile conference presentations that highlight key advances in the field. PMID: 31661150 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - October 28, 2019 Category: Cancer & Oncology Authors: Saleh N Tags: Oncology (Williston Park) Source Type: research

Classifying DLBCL Subtypes for Optimal Treatment.
Abstract DLBCL is the most common subtype of non-Hodgkin lymphoma, representing about 30% to 40% of cases. Patients are typically diagnosed with an excisional lymph node biopsy or a biopsy of another affected organ. When pathologists look under the microscope, they can see a diffused proliferation of large neoplastic B cells. These B cells are identified by flow cytometry or immunohistochemistry that identifies pan-B-cell antigens such as CD19, CD20, and CD79a, as well as CD45. DLBCL is known to be an aggressive lymphoma, but it is also known to be both clinically and molecularly heterogeneous.[1] Patients can hav...
Source: Oncology (Williston Park, N.Y.) - October 28, 2019 Category: Cancer & Oncology Authors: Crombie J Tags: Oncology (Williston Park) Source Type: research

Mutations and the Importance of Genetic Testing.
Abstract There is some controversy over whether every single woman with breast cancer shold have genetic testing, or whether it should only those who have some personal or family history that would suggest their breast cancer may be linked to an inherited mutation. There are also tests of the tumor that look for somatic mutations. Here, we explore the arguments and options. PMID: 31661152 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - October 28, 2019 Category: Cancer & Oncology Authors: Kurian AW Tags: Oncology (Williston Park) Source Type: research

Immunotherapy in Colorectal Cancer.
This article will provide a practical concise overview of the current landscape of immunotherapy in CRC for the practicing oncologist along with a representative case presentation from our community oncology practice. PMID: 31661153 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - October 28, 2019 Category: Cancer & Oncology Authors: Copur MS Tags: Oncology (Williston Park) Source Type: research

Personality Disorders in Patients with Cancer.
Abstract Personality disorders exist on a spectrum in the general population and therefore may coexist in patients who have cancer. Patients with these disorders exhibit character rigidity resulting from enduring patterns of inner experience and behavior and may experience some level of interpersonal conflict among medical staff caring for them. These conditions become exacerbated under stressful cancer-related situations and may lead to adverse consequences and outcomes. This review highlights the conceptual and diagnostic issues of personality disorders for practicing oncologists and provides recommendations for...
Source: Oncology (Williston Park, N.Y.) - October 28, 2019 Category: Cancer & Oncology Authors: McFarland DC, Morita J, Alici Y Tags: Oncology (Williston Park) Source Type: research

Game Changers in Treatment of Hematologic Malignancies.
PMID: 31571178 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - September 20, 2019 Category: Cancer & Oncology Authors: Goy A Tags: Oncology (Williston Park) Source Type: research

67-year-old Male with Prostatic Stromal Tumor of Uncertain Malignant Potential.
PMID: 31571179 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - September 20, 2019 Category: Cancer & Oncology Authors: Bidikov L, Maroni P, Kim S, Crawford ED Tags: Oncology (Williston Park) Source Type: research

Clinical Trials in Breast and Endometrial Cancer.
PMID: 31571180 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - September 20, 2019 Category: Cancer & Oncology Authors: Azvolinsky A, Pangilinan J Tags: Oncology (Williston Park) Source Type: research

Drugs in the Pipeline: Non-Small-Cell Lung Cancer.
PMID: 31571181 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - September 20, 2019 Category: Cancer & Oncology Authors: Saleh N Tags: Oncology (Williston Park) Source Type: research

Biliary Cancer: Current Multimodality Treatment and Future Directions.
Abstract Biliary cancer is a highly aggressive malignancy arising from the biliary tree, with its incidence increasing steadily on a global level. Most biliary cancers are diagnosed in the advanced and metastatic stages due to the paucity of signs and symptoms in the early presentation. Only about one-third of the patients can be treated with curative intent with an overall median survival of less than 24 months for all-comers from the time of diagnosis. This fact and the poor results of the currently available local and systemic therapies, are responsible for the disappointing outcome of biliary cancer patients. ...
Source: Oncology (Williston Park, N.Y.) - September 20, 2019 Category: Cancer & Oncology Authors: Copur MS, Merani S, Vargas LM Tags: Oncology (Williston Park) Source Type: research

Therapy Options for Patients With Hepatocellular Carcinoma.
PMID: 31571183 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - September 20, 2019 Category: Cancer & Oncology Authors: Denlinger C Tags: Oncology (Williston Park) Source Type: research

Practical Dosing Considerations for Venetoclax.
PMID: 31571184 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - September 20, 2019 Category: Cancer & Oncology Authors: Valla K Tags: Oncology (Williston Park) Source Type: research

FDA Approved Uses of Cabozantinib.
PMID: 31571185 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - September 20, 2019 Category: Cancer & Oncology Authors: Leavitt J, Copur MS Tags: Oncology (Williston Park) Source Type: research

Targeting the Sanctuary Site: Options when Breast Cancer Metastasizes to the Brain.
We present our treatment paradigm and multidisciplinary approach to brain metastases arising from breast cancer based on the available evidence, incorporating molecular characteristics. PMID: 31469897 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - August 23, 2019 Category: Cancer & Oncology Authors: Krishnan M, Krishnamurthy J, Shonka N Tags: Oncology (Williston Park) Source Type: research

Pediatric Acute Lymphoblastic Leukemia.
PMID: 31469898 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - August 23, 2019 Category: Cancer & Oncology Authors: Rheingold SR Tags: Oncology (Williston Park) Source Type: research

Management of Steroid-Refractory Immune-Related Adverse Events.
PMID: 31469899 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - August 23, 2019 Category: Cancer & Oncology Authors: Watson ML, Beardslee T Tags: Oncology (Williston Park) Source Type: research

What Are Treatment Options After Progression in PDL-1-Positive Metastatic Lung Adenocarcinoma after Chemo/IO?
PMID: 31469900 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - August 23, 2019 Category: Cancer & Oncology Authors: Remolina-Bonilla YA, Trejo-Rosales RR, Saldivar-Oviedo B, Gabutti A, Bourlon MT Tags: Oncology (Williston Park) Source Type: research

Universal Genetic Testing for All Breast Cancer Patients.
Abstract Women with pathogenic BRCA1/2 mutations are more likely to develop breast cancer than are women without the mutation and they typically develop cancer at an earlier age. If women are aware of their BRCA1/2 status, however, they can make timely decisions about preventive measures such as chemoprevention with hormonal agents or undergoing prophylactic surgery, all of which have been shown to reduce the risk of cancer and overall mortality. The US Preventive Services Task Force and the National Comprehensive Cancer Network have recommended that women with a family history of breast, ovarian, and certain othe...
Source: Oncology (Williston Park, N.Y.) - August 23, 2019 Category: Cancer & Oncology Authors: Copur MS Tags: Oncology (Williston Park) Source Type: research

Atezolizumab and Its Many Uses.
PMID: 31469902 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - August 23, 2019 Category: Cancer & Oncology Authors: Saleh N, Copur MS Tags: Oncology (Williston Park) Source Type: research

Gilteritinib Changes AML Landscape.
PMID: 31469903 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - August 23, 2019 Category: Cancer & Oncology Authors: Saleh N Tags: Oncology (Williston Park) Source Type: research

Current Clinical Trials in Prostate Cancer.
PMID: 31469904 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - August 23, 2019 Category: Cancer & Oncology Authors: Saleh N Tags: Oncology (Williston Park) Source Type: research

Monitoring for Thyroid Cancer Recurrence.
PMID: 31469905 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - August 23, 2019 Category: Cancer & Oncology Authors: Peiris AN Tags: Oncology (Williston Park) Source Type: research

Addressing the Disparities in Prostate Cancer Care and Outcomes.
PMID: 31365747 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - July 16, 2019 Category: Cancer & Oncology Authors: Kittles R Tags: Oncology (Williston Park) Source Type: research

Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit?
Abstract Angiogenesis is known to play an important role in normal ovarian physiology as well as in growth and progression of ovarian cancer. The first FDA approval of bevacizumab in 2004 was for metastatic colorectal cancer in combination with chemotherapy; this was a key point for several subsequent approvals of antiangiogenic drugs. The efficacy of bevacizumab treatment is modest, however, and most ovarian cancer patients eventually develop acquired resistance, which highlights the need for new targeted therapies and/or combination strategies. Understanding the multitude of variables in response to antiangiogen...
Source: Oncology (Williston Park, N.Y.) - July 16, 2019 Category: Cancer & Oncology Authors: Chelariu-Raicu A, Coleman RL, Sood AK Tags: Oncology (Williston Park) Source Type: research

Evolution of Lung Cancer Screening Management.
PMID: 31365749 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - July 16, 2019 Category: Cancer & Oncology Authors: Henschke CI, Yankelevitz DF, Reeves AP, Yip R Tags: Oncology (Williston Park) Source Type: research

Management of Midostaurin-CYP3A4 Drug-Drug Interactions in Patients With Acute Myeloid Leukemia.
PMID: 31365750 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - July 16, 2019 Category: Cancer & Oncology Authors: Schlafer D Tags: Oncology (Williston Park) Source Type: research

ASCO Highlights 2019.
PMID: 31365751 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - July 16, 2019 Category: Cancer & Oncology Authors: Saleh N, Copur MS Tags: Oncology (Williston Park) Source Type: research

Multiple Primary Tumors Over a Lifetime.
Abstract The frequency of patients living after a cancer diagnosis continues to increase due to the rising incidence of cancer as well as the improved survival of cancer patients thanks to advances in cancer research and treatment. The risk of multiple primary cancers is also increasing due to increasing numbers of cancer survivors, long-term side effects of chemotherapy and/or radiation therapy, increased diagnostic sensitivity, and persisting effects of genetic and behavioral risk factors. Multiple primary cancers are defined as more than one synchronous or metachronous cancer in the same individual. Although se...
Source: Oncology (Williston Park, N.Y.) - July 16, 2019 Category: Cancer & Oncology Authors: Copur MS, Manapuram S Tags: Oncology (Williston Park) Source Type: research

Therapy Options in Treating Acute Lymphoblastic Leukemia in Adults.
PMID: 31365753 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - July 16, 2019 Category: Cancer & Oncology Authors: Jabbour E Tags: Oncology (Williston Park) Source Type: research

Diffuse Hepatic Infiltration by Metastatic Melanoma.
on MT PMID: 31365754 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - July 16, 2019 Category: Cancer & Oncology Authors: Velázquez HE, Castro-Alonso FJ, Bourlon C, Gabutti A, Gallegos C, Bourlon MT Tags: Oncology (Williston Park) Source Type: research

Overview: FDA Approval of Olaparib Maintenance for BRCA-Mutated.
PMID: 31365755 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - July 15, 2019 Category: Cancer & Oncology Authors: Saleh N, Copur MS Tags: Oncology (Williston Park) Source Type: research

Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer.
Abstract Detection of the BRAF V600E mutation has important genetic, prognostic, and therapeutic implications for patients with metastatic colorectal cancer (mCRC), as it aids in the identification of a subgroup of patients who derive little benefit from standard treatments and have an extremely poor prognosis. Secondary analyses of BRAF V600E-mutated subsets from multiple randomized clinical trials have demonstrated a lack of therapeutic benefit and poor prognosis with conventional cytotoxic chemotherapy doublets, highlighting the need for novel effective treatments for this subpopulation. In contrast to patients...
Source: Oncology (Williston Park, N.Y.) - June 19, 2019 Category: Cancer & Oncology Authors: Lee HM, Morris V, Napolitano S, Kopetz S Tags: Oncology (Williston Park) Source Type: research

Honing in on Subtypes to Guide More Individualized Treatment of Soft Tissue Sarcoma.
PMID: 31219604 [PubMed - in process] (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - June 19, 2019 Category: Cancer & Oncology Authors: Von Mehren M Tags: Oncology (Williston Park) Source Type: research